The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.
Eisai plots label expansion for subcutaneous Leqembi, details early launch progress
Eisai said it’s planning a rolling FDA submission next month to expand the use of its Biogen-partnered subcutaneous Alzheimer’s treatment, the latest effort to stoke



